Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study

(2012) L. Dalfino et al.   CLINICAL INFECTIOUS DISEASES

Incidence of and Risk Factors for Colistin-Associated Nephrotoxicity in a Large Academic Health System

(2011) J. M. Pogue et al.   CLINICAL INFECTIOUS DISEASES

Colistin pharmacokinetics: the fog is lifting

(2011) W. Couet et al.   CLINICAL MICROBIOLOGY AND INFECTION

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Global spread of drug-resistantAcinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance

(2011) Emanuele Durante-Mangoni et al.   Future Microbiology

Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy

(2011) Maria Giannouli et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii

(2010) M. E. Pachon-Ibanez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

(2010) C. A. DeRyke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Steady-State Pharmacokinetics and BAL Concentration of Colistin in Critically Ill Patients After IV Colistin Methanesulfonate Administration

(2010) Roberto Imberti et al.   CHEST

Treatment ofAcinetobacterInfections

(2010) Joel Fishbain et al.   CLINICAL INFECTIOUS DISEASES

How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrug‐Resistant Bacterial Infection

(2010) David L. Paterson et al.   CLINICAL INFECTIOUS DISEASES

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Global spread of carbapenem-resistant Acinetobacter baumannii

(2009) P. G. Higgins et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

(2008) N. Petrosillo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Acinetobacter baumannii: Emergence of a Successful Pathogen

(2008) A. Y. Peleg et al.   CLINICAL MICROBIOLOGY REVIEWS

Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study

(2008) Nikolaos Markou et al.   CLINICAL THERAPEUTICS

Current control and treatment of multidrug-resistant Acinetobacter baumannii infections

(2008) Drosos E Karageorgopoulos et al.   LANCET INFECTIOUS DISEASES

Acinetobacter Infection

(2008) L. Silvia Munoz-Price et al.   NEW ENGLAND JOURNAL OF MEDICINE